TY - JOUR
T1 - Biological active metabolites from microalgae for healthcare and pharmaceutical industries
T2 - A comprehensive review
AU - Ibrahim, Tengku Nilam Baizura Tengku
AU - Feisal, Nur Azalina Suzianti
AU - Kamaludin, Noor Haziqah
AU - Cheah, Wai Yan
AU - How, Vivien
AU - Bhatnagar, Amit
AU - Ma, Zengling
AU - Show, Pau Loke
N1 - Funding Information:
This work was also supported by the Kurita Water and Environment Foundation (KWEF) [21Pmy004-21R], Fundamental Research Grant Scheme, Malaysia [FRGS/1/2019/STG05/UNIM/02/2], MyPAIR-PHC-Hibiscus Grant [MyPAIR/1/2020/STG05/UNIM/1], The National Natural Science Foundation (No. 41876124) and The Zhejiang Provincial Natural Science Foundation of China (No. LZ21C030001).
Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/3
Y1 - 2023/3
N2 - Microalgae are photoautotrophic microorganisms which comprise of species from several phyla. Microalgae are promising in producing a varieties of products, including food, feed supplements, chemicals, and biofuels. Medicinal supplements derived from microalgae are of a significant market in which compounds such as -carotene, astaxanthin, polyunsaturated fatty acids (PUFA) such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and polysaccharides such as –glucan, are prominent. Microalgae species which are commonly applied for commercial productions include Isochrysis sp., Chaetoceros (Chlorella sp.), Arthrospira sp. (Spirulina Bioactive) and many more. In this present review, microalgae species which are feasible in metabolites production are being summarized. Metabolites produced by microalgae as well as their prospective applications in the healthcare and pharmaceutical industries, are comprehensively discussed. This evaluation is greatly assisting industrial stakeholders, investors, and researchers in making business decisions, investing in ventures, and moving the production of microalgae-based metabolites forward.
AB - Microalgae are photoautotrophic microorganisms which comprise of species from several phyla. Microalgae are promising in producing a varieties of products, including food, feed supplements, chemicals, and biofuels. Medicinal supplements derived from microalgae are of a significant market in which compounds such as -carotene, astaxanthin, polyunsaturated fatty acids (PUFA) such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and polysaccharides such as –glucan, are prominent. Microalgae species which are commonly applied for commercial productions include Isochrysis sp., Chaetoceros (Chlorella sp.), Arthrospira sp. (Spirulina Bioactive) and many more. In this present review, microalgae species which are feasible in metabolites production are being summarized. Metabolites produced by microalgae as well as their prospective applications in the healthcare and pharmaceutical industries, are comprehensively discussed. This evaluation is greatly assisting industrial stakeholders, investors, and researchers in making business decisions, investing in ventures, and moving the production of microalgae-based metabolites forward.
KW - Biological active compounds
KW - Healthcare
KW - Metabolites
KW - Microalgae
KW - Pharmaceutical
UR - http://www.scopus.com/inward/record.url?scp=85147302301&partnerID=8YFLogxK
U2 - 10.1016/j.biortech.2023.128661
DO - 10.1016/j.biortech.2023.128661
M3 - Review article
C2 - 36690215
AN - SCOPUS:85147302301
SN - 0960-8524
VL - 372
JO - Bioresource Technology
JF - Bioresource Technology
M1 - 128661
ER -